Presentation is loading. Please wait.

Presentation is loading. Please wait.

SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain†  Y. Niiyama, T. Kawamata, J. Yamamoto,

Similar presentations


Presentation on theme: "SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain†  Y. Niiyama, T. Kawamata, J. Yamamoto,"— Presentation transcript:

1 SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain†  Y. Niiyama, T. Kawamata, J. Yamamoto, S. Furuse, A. Namiki  British Journal of Anaesthesia  Volume 102, Issue 2, Pages (February 2009) DOI: /bja/aen347 Copyright © 2009 British Journal of Anaesthesia Terms and Conditions

2 Fig 1 Effects of intraperitoneal morphine on bone cancer pain-related behaviours. All behaviours were analysed at day 14 after sarcoma injection. (a) The limb use score during spontaneous ambulation; (b) the weight-bearing score during spontaneous standing; and (c) the number of spontaneous flinches during a 2 min observation period. Values in (a) and (b) were represented as medians with first and third quartiles, and 10th and 90th percentiles. Values in (c) were represented as mean (sd). *P<0.05 vs pre. n=10–11 in each treatment group. ‘Pre’ indicates ‘before the drug administration’. British Journal of Anaesthesia  , DOI: ( /bja/aen347) Copyright © 2009 British Journal of Anaesthesia Terms and Conditions

3 Fig 2 Effects of intraperitoneal SB on bone cancer pain-related behaviours. All behaviours were analysed at day 14 after sarcoma injection. (a) The limb use score during spontaneous ambulation; (b) the weight-bearing score during spontaneous standing; and (c) the number of spontaneous flinches during a 2 min observation period. Values in (a) and (b) were represented as medians with first and third quartiles, and 10th and 90th percentiles. Values in (c) were represented as mean (sd). *P<0.05 vs pre. n=10–11 in each treatment group. ‘Pre’ indicates ‘before the drug administration’. British Journal of Anaesthesia  , DOI: ( /bja/aen347) Copyright © 2009 British Journal of Anaesthesia Terms and Conditions

4 Fig 3 Effects of the combination of morphine and SB on bone cancer pain-related behaviours. All behaviours were analysed at day 14 after sarcoma injection. (a) The limb use score during spontaneous ambulation; (b) the weight-bearing score during spontaneous standing; and (c) the number of spontaneous flinches during a 2 min observation period. Values in (a) and (b) were represented as medians with first and third quartiles, and 10th and 90th percentiles. Values in (c) were represented as mean (sd). *P<0.05 vs pre. n=10–11 in each treatment group. ‘Pre’ indicates ‘before the drug administration’. British Journal of Anaesthesia  , DOI: ( /bja/aen347) Copyright © 2009 British Journal of Anaesthesia Terms and Conditions

5 Fig 4 AUC of morphine alone and the combination of morphine and SB on bone cancer pain-related behaviours. All behaviours were analysed at day 14 after sarcoma injection. (a) The limb use score during spontaneous ambulation; (b) the weight-bearing score during spontaneous standing; and (c) the number of spontaneous flinches during a 2 min observation period. AUC was expressed as means (sd). *P<0.05 vs morphine alone. n=10–11 in each treatment group. NS, not significant. – and + indicate ‘in the absence of SB mg kg−1' and ‘in the presence of SB mg kg−1', respectively. British Journal of Anaesthesia  , DOI: ( /bja/aen347) Copyright © 2009 British Journal of Anaesthesia Terms and Conditions


Download ppt "SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain†  Y. Niiyama, T. Kawamata, J. Yamamoto,"

Similar presentations


Ads by Google